Three's Company: The Battle for Genetic Signatures

Good morning, Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

Previously on… Three’s Company.

A biotech with more cash in the bank than its entire market capitalisation.

That’s Genetic Signatures…

A surprise shareholder buying up stock.

That’s BCAL…

And an unexpected merger partner enters the scene.

That’s Microba…

Cue dramatic recap music 🎶

When we last left off…

BCAL had swooped on Genetic Signatures, acquiring an 18.5% stake.

They weren’t particularly thrilled.

Meanwhile, Genetic Signatures had announced plans to merge with Microba.

BCAL wasn't particularly thrilled either.

So it called a shareholder meeting to remove two Genetic Signatures directors.

And that's where we left things…

But over the past week, the plot has thickened.

A fiery letter to shareholders.

An equally fiery response.

And a showdown is scheduled for 28 October.

… and re-cut merger terms to satisfy just ONE shareholder with the “whip-hand”.

Gloves are off now.

Welcome back to the ASX's favourite biotech soap opera.

But first…

Pro Medicus Limited (ASX: PME) signs a 7-year, A$43M contract with Virtua Health to deploy its cloud-based Visage 7 Enterprise Imaging Platform across Virtua's network. (PME)

🪑 Very, very nice deal.

Telix Pharmaceuticals (ASX: TLX) reports a 19% increase in Q3 2026 revenue (on PcP) to US$245M. (TLX)

Recce Pharmaceuticals (ASX: RCE) announced that its Data Monitoring Committee reviewed the unblinded results and was comfortable there were no safety or tolerability issues. (RCE)

🪑 It was really hard to read between the lines on this one.

The company says it has strong efficacy data across the study population, but it is still waiting on the findings and recommendations.

My take is that this was an interim result, and the DMC's behaviour (not immediately pulling the plug for futility) implies there is enough efficacy beyond futility.

That's just my read…

REPORT: After FDA rejection, Disc Medicine's 'sun allergy' drug hits home run in Phase 3. (Endpoints Capital) 

🪑 Very interesting what happens now to ASX-listed CLINUVEL (ASX: CUV); they have enjoyed a monopoly on their EPP product for several years now. Disc Medicines, however, is hot on their heels, with a real competitor approaching market entry.

Big watch on their AGM - three strikes in a row on the Rem report, going for a fourth.

Invion Limited (ASX: IVX) secures up to A$32.5 million in funding for its clinical trial through an options deal with Point8 Capital and a $7.5 million R&D advance from Rockford. (IVX)

🪑 On face value, this deal looks like a cracker.

IVX is capped at ~$5 million.

They bring in $25 million in exchange for 10% of the company's issued capital (and $7.5 million in an R&D advance)

BUT, Point8 Capital has shown up on one other ASX-listed company, Nexalis (ASX: NX1), and that deal fell over.

IF this is “real”, it’s a very good deal…

Actinogen Medical (ASX: ACW) initiates a “database lock” for its Alzheimer's trial, with results expected mid-November. (ACW)

🪑 Keen to see how this one trades in the run-up to results.

Cleo Diagnostics (ASX: COV) meets performance targets for its prototype ovarian cancer screening test in a proof-of-concept study (n=247). Sensitivity/specificity of 92.2%/98.7% for high-risk and 75.0%/100.0% for the general population. (COV)

🪑 Good start.

The challenge will be replicating these results at scale.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) revised merger terms. Microba to own 60% of GSS (down from 67%), with GSS shareholders holding 40% (up from 33%). (MAP)

Firebrick Pharma (ASX: FRE) launches Nasodine Sinus Rinse in Singapore. (FRE)

A quick note on Starpharma (ASX: SPL): the stock dropped 35% yesterday after it increased its stake in Petalion for $3 million in cash and $2 million in R&D services.

🪑 My take is that this was a “buy the rumour, sell the news” type event. 

Shareholders who wanted to take profits on the company were finally clensed of insider information and could sell their stock… the announcement wasn’t inherently “bad”.

You can see this in the chart: the stock opened at 75 cents (meaning that the market didn’t think it was a disaster)... then the sellers came, and it was a race to the bottom.

My favourite TV episodes were always the ones that gave you each character's POV.

Then, after the ad break… a new character's POV.

Slowly, the story unravels…

Until it all came together in one final scene.

…that's how we're doing this one.

Our first character…

BCAL entered the frame when it bought roughly $3 million in GSS shares, giving it an 18.5% stake.

Also their top shareholder, the Snow Family (through Capital Property Corporation), has picked up another 4.8% of GSS.

That brings the two to a combined 23.3%.

(GSS says it is "currently considering its position" on that… which is a polite way of saying 23.3% is north of the 20% takeover line.)

BCAL initiated a 249D to force the board to call a general meeting to remove GSS directors.

Removing a director needs a simple majority of the shares voted.

The reason?

BCAL outlines this in their “letter to GSS Shareholders”.

Essentially, it boils down to:

(there is a bit more but that is the gist of it)

Instead, BCAL hopes to install Susan Forrester (Chair of Jumbo Interactive, Takeovers Panel member) and Dr John Melki (former GSS CEO from 2011 to 2024).

BCAL also stated its “intentions” for GSS.

I’ll let you read it, but it was more about what WAS NOT there…

… any mention of a merger.

This is big because, under ASIC's "truth in takeovers" policy, ASIC holds BCAL to whatever it says about its intentions.

BCAL also has a $10 million convertible note facility, of which it has drawn $7.6 million.

BCAL shareholders approved the remaining $2.4 million at its AGM on Monday.

(which got voted through)

So why does a company with $1.6 million in the bank (as of last June) and $7.6 million in debt spend $3 million on another company's shares?

BCAL says it's about the platform synergies.

GSS says it's about the cash.

I’ll let you decide.

So… that’s BCAL.

Act I. Scene.

Shortly after the BCAL “Change of Substantial Shareholder” notice, a merger with Genetic Signatures was announced as having been brewing in the background.

Weeks later, Microba disclosed the merger's “proposed terms”.

(Honestly, it was a cracking deal for Microba.)

Microba shareholders would own 67% of the "merged entity", with GSS shareholders getting 33%.

This morning, those terms were re-cut.

Microba now gets 60% of the merged entity, and GSS gets 40%.

A 14 percentage point swing.

(I’ll dive into WHY in a little bit… but it has to do with winning the vote of one key shareholder)

Still, a good deal for Microba.

If Microba raised $20 million at 4 cents (the price it just raised at yesterday), it would be just as dilutive as this merger's terms, 40%.

Think of this like a “capital raise”... but with all of the GSS assets too.

Cracking deal.

… and Microba need it.

The company just put out its 4C report…

ONE quarter of cash to go ($3.87 million in the bank, against $3.8 million of burn).

While there were some one-off expenses, this quarter was broadly in line with Microba’s current cash burn of ~$1 million per month.

So… to top up the coffers, they did a short, sharp capital raise with major shareholders (Sonic Healthcare, Perennial and Thorney).

$2 million at 4 cents.

That’s Microba…

Act II. Scene.

Now to the Final Act of our story.

Genetic Signatures.

It's hard to talk about GSS without talking about the individual pieces within it.

Because you have the board (that represents the company)…

… and you have the shareholders, who ultimately vote.

From the board's perspective, it's clear that they want BCAL OUT.

They've asked shareholders to reject the proposal and have written a letter asking BCAL to announce its merger intentions (if any).

Specifically, they want a statement that BCAL won't pursue a merger before 1 December 2027.

(They can ask… but BCAL doesn't have to answer.)

They’ve also said that IF BCAL's two nominees become the board majority, every remaining GSS director will resign immediately.

(Handing over the keys and saying “good luck”.)

Then there are the shareholders.

Each one has a different interest.

Perennial and Thorney essentially tipped their hand when they were named as two of the three main investors in Microba’s raise yesterday.

Pengana WERE shareholders of GSS, but my understanding is they sold their stake to the Snow family.

Then there is Regal.

In my opinion… “the whip hand”.

Regal is currently sitting at ~7.5%.

Reports say they want the deal recut to value GSS at more than 9 cents per share.

Does this new deal get them there?

YES… it does.

I ran some calculations on the newly re-cut deal (with my trusty friend AI), and the numbers came back flush on 9 cents (based on MAP’s recent 4-cent raise).

Finally, a long tail of retail investors still needs to vote.

This is important because not everyone votes their shares.

(It’s like the US election… turnout matters)

So BCAL could be banking on one critical thing…

Inertia.

If only 70% of shares turn up to vote, BCAL’s 23.3% (between them and the Snow family) becomes more like 33% of the votes cast.

If only 60% turn up, it's closer to 39%.

THEN, flipping one of the major holders (like a Regal) in that scenario could tip them over 50%

So… 

What comes next?

In less than 10 days, we'll know the outcome of BCAL Diagnostics' 249D action against the Genetic Signatures board.

I expect the merger terms between GSS and Microba will be finalised before then.

It won’t get on THIS ticket…

But don’t be surprised if a vote on the merger makes it to the AGM on the 16th November.

Each party will get on the phone to speak to shareholders and make its case.

Proxies close at 10 am on Monday, 26 October.

So…

That’s the state of play.

Until next time.

The Armchair Analyst

See you all tomorrow.